Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2581-2586

  Constantinou, Andreas I ^a,b   Husband, Alan ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Novogen Limited   (Australia)

Author keywords

Antitumor drug; Cleavable complex; DNA cleavage; DNA topoisomerases; Isoflavone; Nicking; Phenoxodiol; Relaxation; Unknotting

Indexed keywords

ANTINEOPLASTIC AGENT; DAIDZEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; ISOFLAVONE DERIVATIVE; PHENOXODIOL; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CATALYSIS; CELL DIVISION; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA PROTEIN COMPLEX; DNA STRAND BREAKAGE; DNA SUPERCOILING; DOSE RESPONSE; ENZYME INHIBITION; HUMAN; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BENZOPYRANS; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA, SINGLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; ISOFLAVONES; PHENOLS;

EID: 0036765911     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kellner U, Rudolph P and Parwaresch R: Human DNA- topoisomerases - diagnostic and therapeutic implications for cancer. Onkologie 23: 424-430, 2000.
2. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
3. Constantinou A, Kiguchi K and Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50: 2618-2624, 1990.
4. Kiguchi K, Constantinou AI and Huberman E: Genistein-induced cell differentiation and protein-linked DNA strand breakage in human melanoma cells. Cancer Commun 2: 271-277, 1990.
5. Okura A, Arakawa H, Oka H, Yoshinari T and Monden Y: Effect of genistein on topoisomerase activity and on the growth of (Val 12)Haras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 157: 183-189, 1988.
6. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A and Moon R: Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 58: 217-225, 1995.
7. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB and Larsen AK: Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49: 5111-5117, 1989.
8. Heck MM and Earnshaw WC: Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 103: 2569-2581, 1986.
9. Heck MM, Hittelman WN and Earnshaw WC: Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086-1090, 1988.
10. Davis JN, Singh B, Bhuiyan M and Sarkar FH: Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32: 123-131, 1998.
11. Deffie AM, Bosman DJ and Goldenberg GJ: Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Cancer Res 49: 6879-6882, 1989.
12. Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper JT and Levine A: Treatment of therapy- refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 5: 3906-3913, 1999.
13. Strick R, Strissel PL, Borgers S, Smith SL and Rowley JD: Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 97: 4790-4795, 2000.
14. Liu LF, Davis JL and Calendar R: Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases. Nucleic Acids Res 9: 3979-3989, 1981.
15. Hansen HH: Management of small-cell cancer of the lung. Lancet 339: 846-849, 1992.
16. Beere HM, Chresta CM, Alejo-Herberg A, Skladanowski A, Dive C, Larsen AK and Hickman JA: Investigation of the mechanism of higher order chromatin fragmentation observed in drug-induced apoptosis. Mol Pharmacol 47: 986-996, 1995.
17. Snapka RM, Kwok K, Bernard JA, Harling OK and Varshavsky A: Post-separation detection of nucleic acids and proteins by neutron activation. Proc Natl Acad Sci USA 83: 8939-8942, 1986.
18. Burden DA and Osheroff N: Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 139-154, 1998.
19. Fortune JM, Osheroff N: Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64: 221-253, 2000.
20. Jensen PB and Sehested M: DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54: 755-759, 1997.
21. Meng LH, Zhang JS and Ding J: Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes. Biochem Pharmacol 62: 733-741, 2001.